Ling‐Min Kong
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- Signaling Pathways in Disease
- RNA modifications and cancer
- Circular RNAs in diseases
- Epigenetics and DNA Methylation
Papers in
-
- Signaling Pathways in Disease 7
- RNA modifications and cancer 4
- Cancer-related gene regulation 3
- FOXO transcription factor regulation 2
- Circular RNAs in diseases 2
- Epigenetics and DNA Methylation 2
-
- Galectins and Cancer Biology 4
- Co-authors
- Zhi‐Nan Chen (15 shared papers)Cheng‐Gong Liao (10 shared papers)Huijie Bian (13 shared papers)Jinliang Xing (3 shared papers)Jing Xu (3 shared papers)Yang Zhang (2 shared papers)Wan Huang (1 shared paper)Yi Zhang (1 shared paper)
- Journals
- Oncotarget (2 papers)Biochemical and Biophysical Research Communications (1 paper)Cancer Letters (1 paper)Cancer Cell International (1 paper)Medical Oncology (1 paper)
- Partner nations
- ChinaUnited StatesIndia
In The Last Decade
Ling‐Min Kong
21 papers receiving 810 citations
Peers
Comparison fields: 5 of 75
- Cancer Research 204
- Molecular Biology 550
- Immunology 117
- Hepatology 37
- Oncology 124
Countries citing papers authored by Ling‐Min Kong
This map shows the geographic impact of Ling‐Min Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling‐Min Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling‐Min Kong more than expected).
Fields of papers citing papers by Ling‐Min Kong
This network shows the impact of papers produced by Ling‐Min Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling‐Min Kong. The network helps show where Ling‐Min Kong may publish in the future.
Co-authors
The 25 scholars most cited alongside Ling‐Min Kong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 138 | |
| 2 | 2010 | 92 | |
| 3 | 2012 | 82 | |
| 4 | 2015 | 70 | |
| 5 | 2011 | 69 | |
| 6 | 2014 | 64 | |
| 7 | 2010 | 53 | |
| 8 | 2021 | 44 | |
| 9 | 2006 | 42 | |
| 10 | 2007 | 32 | |
| 11 | 2022 | 22 | |
| 12 | 2016 | 20 | |
| 13 | 2012 | 19 | |
| 14 | 2023 | 19 | |
| 15 | 2022 | 13 | |
| 16 | 2024 | 12 | |
| 17 | 2016 | 8 | |
| 18 | 2018 | 6 | |
| 19 | 2023 | 5 | |
| 20 | 2025 | 4 |
About Ling‐Min Kong
Ling‐Min Kong is a scholar working on Molecular Biology, Immunology, Cancer Research, Surgery and Oncology, having authored 22 papers that have together received 815 indexed citations. Recurring topics across this work include Signaling Pathways in Disease (7 papers), Galectins and Cancer Biology (4 papers), RNA modifications and cancer (4 papers), Cancer-related gene regulation (3 papers), FOXO transcription factor regulation (2 papers), Endoplasmic Reticulum Stress and Disease (2 papers), Circular RNAs in diseases (2 papers) and Epigenetics and DNA Methylation (2 papers). The work is most often cited by research in Cancer Research (204 citations), Molecular Biology (550 citations), Immunology (117 citations), Hepatology (37 citations) and Oncology (124 citations). Ling‐Min Kong has collaborated with scholars based in China, United States and India. Frequent co-authors include Zhi‐Nan Chen, Cheng‐Gong Liao, Huijie Bian, Jinliang Xing, Jing Xu, Yang Zhang, Wan Huang, Yi Zhang, Yu Li and Fei Fei. Their work appears in journals such as Oncotarget, Biochemical and Biophysical Research Communications, Cancer Letters, Cancer Cell International and Medical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.